

13 April 2017

Australian Securities Exchange
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

Appendix 3Y

Please find attached Appendix 3Y, Change of Director's Interest Notice for Mr Leedman.

As announced on 22 March 2017, Mr Leedman exercised 5,000,000 Options over ordinary shares in Alcidion Group Limited ("Company"). Following the release of the Company's Quarterly Cashflow Statement, and in compliance with the Company's share trading policy, he has subsequently divested the resulting ordinary shares.

Mr Leedman commented, "Alcidion should be commended on developing a world class Clinical Decision Support Platform and is well positioned to action its commercialisation strategy. The recent divestment of the Alcidion equities is no reflection on the position of the Company, but rather it is to free up some personal funds."

The Company has 607,779,957 ordinary shares on Issue, with over 57% of the shares controlled by its founders, employees and early stage investors, as detailed below:

Shareholder	Shares	Percentage
Professor Malcolm Pradhan	134,582,403	22.14%
Mr Raymond Blight & Ms Robyn Morris	97,051,003	15.97%
BSPE Medical Technology Pty Ltd ATF BSPE Medical Technology Unit Trust	84,864,273	13.96%
Allure Capital	19,176,071	3.16%
Employees	11,154,733	1.84%
Others	260,951,474	42.94%

Yours faithfully,



Raymond Blight
Chief Executive Officer & Chairman

ENDS

For further information, please contact:

Nathan Buzza, Executive Director

Ph: +61 (0) 488862222

Alcidion Group Limited

nathan.buzza@alcidion.com

Ray Blight, Chief Executive Officer

Ph: +61 (08) 8208 4600

Alcidion Group Limited

ray.blight@alcidion.com

About Alcidion

Alcidion Group Limited (ASX: **ALC**) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

13 April 2017

Australian Securities Exchange
 Level 40, Central Park
 152-158 St George's Terrace
 Perth WA 6000

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	BRIAN LEEDMAN
Date of last notice	22/3/2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	10 APRIL TO 12 APRIL 2017
No. of securities held prior to change	5,000,000 FULLY PAID ORDINARY SHARES 10,000,000 UNLISTED OPTIONS
Class	FULLY PAID ORDINARY SHARES
Number acquired	
Number disposed	5,000,000 FULLY PAID ORDINARY SHARES

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$343,859 FOR DISPOSAL OF FULLY PAID ORDINARY SHARES
No. of securities held after change	10,000,000 UNLISTED OPTIONS <ul style="list-style-type: none"> - 5,000,000 @ \$0.06 exercisable after release of Appendix 4E for financial year ending 30 June 2017 - 5,000,000 @ \$0.08 exercisable after release of Appendix 4E for financial year ending 30 June 2018 All 10,000,000 unlisted options have an option exercise expiry date of 30 June 2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	ON-MARKET TRADES

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

ENDS

For further information, please contact:

Duncan Craig

Chief Financial Officer and Company Secretary
 Ph: +61 (08) 8208 4600
 Alcidion Corporation
duncan.craig@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies